6.63
1.69%
+0.11
Axogen Inc. stock is currently priced at $6.63, with a 24-hour trading volume of 418.16K.
It has seen a +1.69% increased in the last 24 hours and a -12.19% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.62 pivot point. If it approaches the $6.77 resistance level, significant changes may occur.
Previous Close:
$6.52
Open:
$6.53
24h Volume:
418.16K
Market Cap:
$289.65M
Revenue:
$159.01M
Net Income/Loss:
$-21.72M
P/E Ratio:
-11.84
EPS:
-0.56
Net Cash Flow:
$-20.63M
1W Performance:
+2.00%
1M Performance:
-12.19%
6M Performance:
+80.16%
1Y Performance:
-27.78%
Axogen Inc. Stock (AXGN) Company Profile
Name
Axogen Inc.
Sector
Industry
Phone
386-462-6800
Address
13631 Progress Boulevard, Suite 400, Alachua, FL
Axogen Inc. Stock (AXGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-11-22 | Resumed | Jefferies | Buy |
May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-23-20 | Initiated | Guggenheim | Buy |
Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-12-19 | Initiated | Canaccord Genuity | Buy |
Mar-02-18 | Reiterated | Lake Street | Buy |
Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
Nov-30-17 | Initiated | Jefferies | Buy |
Nov-21-17 | Reiterated | Lake Street | Buy |
Jul-31-17 | Initiated | Leerink Partners | Outperform |
Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
Mar-06-17 | Initiated | ROTH Capital | Buy |
Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
Nov-07-16 | Reiterated | Wedbush | Outperform |
Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
Aug-04-16 | Reiterated | Wedbush | Outperform |
May-14-14 | Initiated | Dawson James | Buy |
Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc. Stock (AXGN) Latest News
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire Inc.
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
GlobeNewswire Inc.
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
Zacks Investment Research
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Zacks Investment Research
Axogen Inc. Stock (AXGN) Financials Data
Axogen Inc. (AXGN) Revenue 2024
AXGN reported a revenue (TTM) of $159.01 million for the quarter ending December 31, 2023, a +14.74% rise year-over-year.
Axogen Inc. (AXGN) Net Income 2024
AXGN net income (TTM) was -$21.72 million for the quarter ending December 31, 2023, a +24.98% increase year-over-year.
Axogen Inc. (AXGN) Cash Flow 2024
AXGN recorded a free cash flow (TTM) of -$20.63 million for the quarter ending December 31, 2023, a +44.71% increase year-over-year.
Axogen Inc. (AXGN) Earnings per Share 2024
AXGN earnings per share (TTM) was -$0.52 for the quarter ending December 31, 2023, a +23.53% growth year-over-year.
About Axogen Inc.
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Cap:
|
Volume (24h):